Citruspharma

Citruspharma is a Netherlands-based biotechnology company focused on developing first-in-class small molecule inhibitors for the treatment of metabolic diseases. The company specifically targets the SLC13A5 transporter, a key regulator of hepatic citrate uptake that drives de novo lipogenesis and contributes to metabolic dysfunction. By blocking this transporter, Citruspharma's lead programs aim to address the underlying drivers of metabolic dysfunction-associated steatohepatitis (MASH), obesity, and type 2 diabetes. Founded as a spin-off from the Amsterdam University Medical Center, the company leverages deep expertise in metabolic pathways and transporter biology. Citruspharma is currently advancing its lead candidates through preclinical development with the support of specialized life science investors.